Country: Suður-Afríka
Tungumál: enska
Heimild: South African Health Products Regulatory Authority (SAHPRA)
Lennon
LENAMET™-200 TABLETS LENAMET™-400 TABLETS LENAMET™ INJECTION 200 mg/2 mL SCHEDULING STATUS: S3 PROPRIETARY NAME (and dosage form): LENAMET™-200 TABLETS LENAMET™-400 TABLETS LENAMET™ INJECTION 200 mg/2 mL COMPOSITION: Each tablet contains 200 mg or 400 mg Cimetidine respectively. Each ampoule contains 200 mg Cimetidine per 2 mL. PHARMACOLOGICAL CLASSIFICATION: A 11.4.3 Medicines acting on gastro-intestinal tract: Other. PHARMACOLOGICAL ACTION: Cimetidine is a histamine H2-receptor antagonist. Its main action is to inhibit gastric acid secretion. It also inhibits competitively the other actions of histamine mediated by H2-receptors. The decrease in gastric acid secretion occurs regardless of the nature of the physiological stimulus to secretion, i.e. basal or unstimulated secretion, is reduced. Both the volume of secretion and the concentration of acid in the secretion are reduced. INDICATIONS: The treatment of benign gastric and duodenal ulcers, reflux oesophagitis, Zollinger-Ellison syndrome and in other conditions associated with gastric hypersecretory states, such as systemic mastocytosis and multiple endocrine adenomas. It is also indicated at reduced dosage for duodenal ulcer recurrence in selected patients. CONTRA-INDICATIONS: Lenamet is not recommended for minor digestive complaints. It is also not recommended for patients with impaired renal function. DOSAGE AND DIRECTIONS FOR USE: Clinical experience with Lenamet in children is limited. Therefore Lenamet therapy cannot be recommended for children. The total daily use by any route should not exceed 2,4 g. Oral: Treatment should be continued for at least 4 weeks. Duodenal ulcer: 400 mg twice daily and at bedtime, or 800 mg at bedtime. Maintenance dose for recurrent duodenal ulcer: One 400 mg tablet at bedtime. Benign active Lestu allt skjalið